Unlock STING polymorphism with a comprehensive HTRF binding platform

STING protein is a mediator of innate immunity and a candidate for auto immune disease or cancer immunotherapy. Clinical trials are already ongoing, and targeting all STING variants has become crucial. R232 is the most common variant, and HAQ and H232 alleles are also present in the human population.

To help you identify and characterize universal new STING therapeutics, Revvity has developed this note with:

  • How HTRF human and mouse STING assays are built up,
  • What their main features are,
  • How the most relevant and promising STING agonists, like ADU-S100, behave towards the different STING variants.